用转谷氨酰胺酶 2 抑制剂治疗乳糜泻的转录组分析

IF 27.7 1区医学 Q1 IMMUNOLOGY

Nature Immunology Pub Date : 2024-07-01 DOI:10.1038/s41590-024-01870-5

引用次数: 0

摘要

ZED1227是一种转谷氨酰胺酶2抑制剂，其对乳糜泻疗效的分子基础尚不清楚。我们的研究表明，口服 ZED1227 能在转录组水平上有效预防麸质诱导的肠道损伤和炎症，而且高危 HLA II 类乳糜泻患者会持续显示出更 "恶化 "的分子表型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Transcriptomic analysis of celiac disease treatment with transglutaminase 2 inhibitor

查看原文本刊更多论文

Transcriptomic analysis of celiac disease treatment with transglutaminase 2 inhibitor

The molecular basis for the efficacy of ZED1227 — a transglutaminase 2 inhibitor — in celiac disease is unknown. We show that orally administered ZED1227 effectively prevented gluten-induced intestinal damage and inflammation at the transcriptome level, and that individuals with high-risk HLA class II celiac disease consistently display a more ‘deteriorated’ molecular phenotype.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Immunology 医学-免疫学

CiteScore

40.00

自引率

2.30%

发文量

248

审稿时长

4-8 weeks

期刊介绍： Nature Immunology is a monthly journal that publishes the highest quality research in all areas of immunology. The editorial decisions are made by a team of full-time professional editors. The journal prioritizes work that provides translational and/or fundamental insight into the workings of the immune system. It covers a wide range of topics including innate immunity and inflammation, development, immune receptors, signaling and apoptosis, antigen presentation, gene regulation and recombination, cellular and systemic immunity, vaccines, immune tolerance, autoimmunity, tumor immunology, and microbial immunopathology. In addition to publishing significant original research, Nature Immunology also includes comments, News and Views, research highlights, matters arising from readers, and reviews of the literature. The journal serves as a major conduit of top-quality information for the immunology community.